Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium

Endocrinology

Volumn 137, Issue 1, 1996, Pages 219-224

  Nephew, Kenneth P ^a   Polek, Tara C ^a   Khan, Sohaib A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL FUNCTION; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HISTOLOGY; HORMONAL REGULATION; IN SITU HYBRIDIZATION; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTO ONCOGENE;

EID: 0030038898     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.1.8536616     Document Type: Article

References (61)

1. Kelloff GJ, Crowell JA, Boone CA, Steele VA, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC 1994 Clinical development plans for cancer chemopreventive agents. J Cell Biochem Suppl 20:252-267
2. Harper MJK, Walpole AL 1967 A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13:101-119
3. Clark JH, Anderson JN, Peck, Jr, EJ 1973 Estrogen receptor antiestrogen complex: atypical binding by uterine nuclei and effects on uterine growth. Steroids 22:707-718
4. Martin L, Middleton E 1978 Prolonged oestrogenic and mitogenic activity of tamoxifen in the ovariectomized mouse. J Endocrinol 78:125-129
5. Nayfield SG, Karp JE, Ford LG, Dorr A, Kramer BS 1991 Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459
6. Neven P, de Muylder X, van Belle Y, Campo R, Vanderick G 1994 Tamoxifen and the uterus. Br Med J 309:1313-1314
7. Jordan VC, Morrow M 1994 Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 11:1714-1721
8. Friedl A, Jordan VC 1994 What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31:27-39
9. Fischer B, Constantino J, Redmond C, Fisher E, Wickerham L, Cronin W 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst 86:527-537
10. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrere CHF, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebolt AW, van Tinteren H 1994 Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452
11. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML 1993 High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490
12. Silva EG, Tornos CS, Follen-Mitchell M 1994 Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13:248-258
13. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G 1990 Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37:378-380
14. Gurpide E 1991 Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 83:405-416
15. Murphy LJ 1994 Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol 48:419-423
16. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, Beyth Y 1993 Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynecol 100:567-570
17. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S 1994 Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321
18. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, Beyth Y 1994 Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185-190
19. Nephew KP, Polek TC, Akcali KC, Khan SA 1993 The antiestrogen tamoxifen induces c-fos and jun-B, but not c-jun and jun-D, protooncogenes in the rat uterus. Endocrinology 133:419-422
20. Kirkland JL, Murthy L, Stancel GM 1993 Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus. Mol Pharmacol 43:709-714
21. Khan SA, Nephew KP, Wang H 1994 The jun protooncogene family in uterine growth and differentiation. In: Khan SA, Stancel GM (eds) Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation. CRC Press, Boca Raton, FL, pp 105-124
22. Stancel GM, Boettger-Tong H, Hyder SM, Kirkland JL, Loose-Mitchell DS 1994 Uterine c-fos: a paradigm for control of gene expression during estrogen stimulated target tissue growth. In: Khan SA, Stancel GM (eds) Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation. CRC Press, Boca Raton, FL, pp 87-104
23. Curran T, Franza, Jr, BR 1988 Fos and Jun: the AP-1 connection. Cell 55:395-397
24. Bravo R 1990 Growth factor-responsive genes in fibroblasts. Cell Growth & Differ 1:305-309
25. Angel P, Karin M 1991 The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157
26. Waters AP, Knowler JT 1980 A comparison of the effects of oestrogen and tamoxifen on the synthesis of uterine RNA in immature rats. J Steroid Biochem 14:625-630
27. Wakeling AE, Bowler J 1988 Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645-653
28. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC 1990 Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43
29. Nephew KP, Tang M, Khan SA 1994 Estrogen differentially affects c-jun expression in uterine tissue compartments. Endocrinology 134: 1827-1834
30. Nephew KP, Peters GA, Khan SA 1995 Cellular localization of estradiol-induced c-fos messenger ribonucleic acid in the rat uterus: c-fos expression and uterine cell proliferation do not correlate strictly. Endocrinology 136:3007-3015
31. Hsu CYJ, Komm B S, Lyttle CR, Frankel F 1988 Cloning of estrogen-regulated messenger ribonucleic acids from rat uterus. Endocrinology 122:631-639
32. Jordan VC, Dix CJ 1979 Effect of oestradiol benzoate, tamoxifen and monohydroxytamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division. J Steroid Biochem 11:285-291
33. Katzenellenbogen BS, Bhakoo HS, Ferguson ER, Lan NC, Tatee T, Tsai TS, Katzenellenbogen JA 1979 Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res 35:259-292
34. Dix CJ, Jordan VC 1980 Subcellular effects of monohydroxytamox-ifen in the rat uterus: steroid receptors and mitosis. J Endocrinol 85:393-404
35. Holinka CF, Bressler RS, Zehr DR, Gurpide E 1980 Comparison of effects of estetrol and tamoxifen with those of estriol and estradiol on the immature rat uterus. Biol Reprod 22:913-926
36. Lyman SD, Jordan VC 1985 Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol 34:2787-2794
37. Branham WS, Sheehan DM, Zehr DR, Medlock KL, Nelson CJ, Ridlon E 1985 Inhibition of rat uterine gland genesis by tamoxifen. Endocrinology 117:2238-2248
38. Galman MS, Sundstrom SA, Lyttle CR 1990 Antagonism of estrogen- and antiestrogen-induced uterine complement component C3 expression by ICI 164,384. J Steroid Biochem 36:281-286
39. Branham WS, Zehr DR, Sheehan DM 1993 Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc Soc Exp Biol Med 203:297-303
40. Rumpel E, Michna H, Wolfgang K 1995 PCNA-immunoreactivity in the uterus of rats after treatment with the antiestrogen tamoxifen. Ann Anat 177:133-138
41. Weisz A, Bresciani F 1988 Estrogen induces expression of c-fos and c-myc proto-oncogenes in rat uterus. Mol Endocrinol 2:816-824
42. Bigsby RM, Aixin L 1994 Differentially regulated immediate early genes in the rat uterus. Endocrinology 134:1820-1826
43. Ramkumar T, Adler S 1995 Differential positive and negative transcriptional regulation by tamoxifen. Endocrinology 136:536-542
44. Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456
45. Hyder SM, Stancel GM, Loose-Mitchell DS 1991 Presence of an estradiol response region in the mouse c-fos oncogene. Steroids 56:498-504
46. Hyder SM, Stancel GM, Nawaz Z, McDonnel DP, Loose-Mitchell DS 1992 Identification of an estrogen response element in the 3′-flanking region of the mouse c-fos protooncogene. J Biol Chem 267: 18047-18054
47. Hyder SM, Stancel GM 1994 In vitro interaction of uterine estrogen receptor with the estrogen response element present in the 3′-flanking region of the murine c-fos protooncogene. J Steroid Biochem Mol Biol 48:69-79
48. Hyder SM, Nawaz Z, Chiappetta C, Yokoyama K, Stancel GM 1995 The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence. J Biol Chem 270:8506-8513
49. Huynh HT, Pollak M 1993 Insulin-like growth factor-1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53:5585-5588
50. Sartor BM, Sartor O, Flanders KC 1995 Analogous tamoxifen and estrogen effects on transforming growth factor-betas 1 and 2 in the rat uterus. Reprod Toxicol 9:225-231
51. Murphy LJ, Ghahary A 1990 Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 11:443-453
52. Busslinger M, Bergers G 1994 Identification of AP-1-regulated genes. In: Angel PE, Herrlich PA (eds) The Fos and Jun Families of Transcription Factors. CRC Press, Boca Raton, FL, pp 133-150
53. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P 1988 c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55:917-924
54. Ryseck RP, Bravo R 1990 c-Jun, Jun-B and Jun-D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of Fos proteins. Oncogene 6:533-542
55. Curran T, Vogt PK 1992 Dangerous liaisons: Fos and Jun, oncogenic transcription factors, p. 797-831. In: McKnight SL, Yamamoto KR (eds) Transcriptional Regulation. Cold Spring Harbor Press, Cold Spring Harbor, NY, vol 2:797-831
56. Muller R 1994 Role of Fos proteins in the induction of transformation and DNA synthesis. In: Angel PE, Herrlich PA (eds) The Fos and Jun Families of Transcription Factors. CRC Press, Boca Raton, FL, pp 193-202
57. Vogt PK 1994 Oncogenic transformation by Jun. In: Angel PE, Herrlich PA (eds) The Fos and Jun Families of Transcription Factors. CRC Press, Boca Raton, FL, pp 203-219
58. Bossy-Wetzel E, Bravo R, Hanahan D 1992 Transcription factors Jun-B and c-Jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Genes Dev 6:2340-2351
59. Liehr JG, Chiappetta C, Roy D, Stancel GM 1992 Elevation of protooncogene messenger RNA in estrogen-induced kidney tumors in the hamster. Carcinogenesis 13:601-604
60. Sakakibara K, Kan NC, Satyaswaropp PG 1992 Both 17β-estradiol and tamoxifen induce c-fos messenger ribonucleic acid expression in human endometrial carcinoma grown in nude mice. Am J Obstet Gynecol 166:206-212
61. Miao GG, Curran T 1994 Cell transformation by c-fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 14:4295-4310.